821 TCR
Alternative Names: 821-TCRLatest Information Update: 08 Feb 2023
At a glance
- Originator T-Cure
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 12 Jan 2023 Preclinical trials in Solid tumours in USA (Parenteral) on or before January 2023 (T-cure pipeline; January 2023)